Oral Complications of Radiation Therapy Clinical Trial
Official title:
Pulsed Dye Laser for Treatment of Post Radiation Dysphonia
Verified date | April 2023 |
Source | Wake Forest University Health Sciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This pilot trial studies pulsed dye laser in treating patients with post radiation dysphonia. Dysphonia, or vocal cord scarring, can include trouble with the voice when trying to talk, such as hoarseness, change in voice pitch, and poor voice quality, and it commonly happens after radiation therapy for laryngeal cancer. Pulsed dye laser may improve post radiation dysphonia.
Status | Completed |
Enrollment | 9 |
Est. completion date | June 2016 |
Est. primary completion date | June 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Patients suffering from dysphonia after radiation therapy for glottic carcinoma will be included in the study - Patients will be included if their initial stage was T1 N0 M0 or T2 N0 M0 Exclusion Criteria: - Patients having previously undergone large surgical resections of the larynx or hypopharynx will be excluded - Patients fewer than 1 year out from completion of radiation therapy will be excluded - Patients with local disease recurrence would be excluded from the trial - Patients in whom the transnasal endoscope is poorly tolerated or patients in whom transnasal endoscopic laryngoscopy is contraindicated will be excluded |
Country | Name | City | State |
---|---|---|---|
United States | Comprehensive Cancer Center of Wake Forest University | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Wake Forest University Health Sciences | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Videostroboscopy rates | Forced choice comparisons will be utilized in the pre and post treatment stroboscopy comparisons. | Up to 6 months post-treatment | |
Primary | Change in Voice Handicap Index (VHI)-10 score | The VHI-10 form will be scored and then those numbers will be compared pre and post treatment for each individual. | Baseline to 6 months post-treatment | |
Primary | Change in jitter | Laboratory based voice analysis will be performed with evaluations of aerodynamics and acoustics. | Baseline and at 6 months post-treatment | |
Primary | Voice quality using the patient self-assessment questionnaire | The post treatment questionnaire form will be scored and then comparisons made for each individual question on the form across our study group. These values will be discrete variables. | Up to 6 months post-treatment | |
Primary | Change in shimmer | Laboratory based voice analysis will be performed with evaluations of aerodynamics and acoustics. | Baseline and at 6 months post-treatment | |
Primary | Change in noise to harmonic ratio | Laboratory based voice analysis will be performed with evaluations of aerodynamics and acoustics. | Baseline and at 6 months post-treatment | |
Primary | Change in mean phonatory flow | Laboratory based voice analysis will be performed with evaluations of aerodynamics and acoustics. | Baseline and at 6 months post-treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01155609 -
L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer
|
N/A | |
Completed |
NCT00415025 -
Side Effects of High-Dose Intensity-Modulated Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer
|
N/A | |
Completed |
NCT00057785 -
Radiation Therapy With or Without Chemotherapy in Reducing Mouth Dryness in Patients With Nasopharyngeal Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01156142 -
Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy
|
Phase 3 | |
Active, not recruiting |
NCT00022373 -
Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer
|
Phase 3 | |
Withdrawn |
NCT01545687 -
CD2 Lozenges in Preventing Acute Oral Mucositis in Patients With Head and Neck Cancer Receiving Radiotherapy and Chemotherapy
|
Phase 3 |